KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Total Debt (2016 - 2025)

Historic Total Debt for Idexx Laboratories (IDXX) over the last 17 years, with Q3 2025 value amounting to $829.8 million.

  • Idexx Laboratories' Total Debt rose 710.76% to $829.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $829.8 million, marking a year-over-year increase of 710.76%. This contributed to the annual value of $699.8 million for FY2024, which is 1983.05% down from last year.
  • As of Q3 2025, Idexx Laboratories' Total Debt stood at $829.8 million, which was up 710.76% from $1.0 billion recorded in Q2 2025.
  • In the past 5 years, Idexx Laboratories' Total Debt ranged from a high of $1.4 billion in Q3 2022 and a low of $699.8 million during Q4 2024
  • Its 5-year average for Total Debt is $936.1 million, with a median of $872.9 million in 2023.
  • In the last 5 years, Idexx Laboratories' Total Debt soared by 6339.85% in 2022 and then crashed by 3766.65% in 2023.
  • Quarter analysis of 5 years shows Idexx Laboratories' Total Debt stood at $850.2 million in 2021, then rose by 11.08% to $944.4 million in 2022, then fell by 7.57% to $872.9 million in 2023, then fell by 19.83% to $699.8 million in 2024, then grew by 18.58% to $829.8 million in 2025.
  • Its Total Debt was $829.8 million in Q3 2025, compared to $1.0 billion in Q2 2025 and $769.3 million in Q1 2025.